Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised,Double-blind,Placebo-controlled,Multinational,Multi-centre,Phase IIb/III Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy (SLIT) Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis

NCT00367640 is registered in ClinicalTrials.gov with Stallergenes Greer as lead sponsor.

NCT NCT00367640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00367640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised,Double-blind,Placebo-controlled,Multinational,Multi-centre,Phase IIb/III Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy (SLIT) Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis
Lead sponsor
Stallergenes Greer
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2004
Completion date
September 30, 2005
Enrollment
628 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergy